CUPR · Cuprina Holdings (Cayman) LTD
$3.60
-0.01 (-0.28%)
At close · Jul 28
Market Cap
$26.59M
Shares
7.37M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
49.89K
+3.3%
FY2025
Net Income
-4.67M
-199.5%
FY2025
Diluted EPS
-1.83
-165.2%
FY2025
Operating Cash Flow
-9.13M
-639%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| SGD | 49.89K | 48.32K | 100.77K | 56.6K |
| SGD | -14.72K | -37.21K | -56.59K | -2017 |
| SGD | 50.54K | 51.35K | 64.17K | 36.62K |
| SGD | -645 | -3024 | 36.61K | 19.98K |
| SGD | 226.88K | 241.36K | 167.73K | 292.88K |
| SGD | 4.6M | 1.4M | 937.2K | 902.89K |
| SGD | 36.52K | 42.19K | 35.06K | 29.09K |
| SGD | 4.83M | 1.64M | 1.1M | 1.2M |
| SGD | -4.83M | -1.65M | -1.07M | -1.18M |
| SGD | 14.72K | 1783 | 727 | 1842 |
| SGD | 219.73K | 136.66K | -17.44K | 88.62K |
| SGD | -4.61M | -1.51M | -1.09M | -1.09M |
| SGD | -4.67M | -1.56M | -1.12M | -1.09M |
| SGD | -4.32M | -1.56M | -1.12M | -1.09M |
| SGD/shares | -1.83 | -0.69 | -0.50 | -48.64 |
| SGD/shares | -1.83 | -0.69 | -0.50 | -48.64 |
| shares | 2.56M | 2.25M | 2.25M | 2.25M |
| shares | 2.56M | 2.25M | 2.25M | 2.25M |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 1.29×
EV/EBIT
—
P/E (TTM)
—
Peer median 18.20×
Peer medians compare against the 18 similar-size Medical Instruments & Supplies companies (of 50 listed).
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (SGD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Maggot Debridement Therapy Product | 44,204 | 34,417 | 78,957 | 56,599 |
| Cosmeceutical Product | 5,690 | 13,904 | 21,816 | — |